Bahl & Gaynor Inc Gilead Sciences, Inc. Transaction History

Bahl & Gaynor Inc

$19.3 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$71.58 - $87.29 $742,857 - $905,895	-10,378 Reduced 77.51%	3,012 $220,000
Q4 2023 Feb 02, 2024	SELL	$73.27 - $83.09 $84,626 - $95,968	-1,155 Reduced 7.94%	13,390 $1.08 Million
Q3 2023 Nov 03, 2023	SELL	$73.94 - $80.67 $81,186 - $88,575	-1,098 Reduced 7.02%	14,545 $1.09 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $20,066 - $22,888	264 Added 1.72%	15,643 $1.21 Million
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $231,852 - $264,151	-2,999 Reduced 16.32%	15,379 $1.28 Million
Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $248,594 - $356,895	3,989 Added 27.72%	18,378 $1.58 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $10,121 - $11,561	-170 Reduced 1.17%	14,389 $888,000
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $13,102 - $14,757	227 Added 1.58%	14,559 $900,000
Q1 2022 May 12, 2022	BUY	$57.92 - $72.58 $12,916 - $16,185	223 Added 1.58%	14,332 $852,000
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $221,759 - $251,701	-3,418 Reduced 19.5%	14,109 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $2,910 - $3,140	-43 Reduced 0.24%	17,527 $1.22 Million
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $17,327 - $18,932	-273 Reduced 1.53%	17,570 $1.21 Million
Q1 2021 May 11, 2021	SELL	$60.0 - $68.46 $168,540 - $192,304	-2,809 Reduced 13.6%	17,843 $1.15 Million
Q4 2020 Feb 02, 2021	BUY	$56.65 - $64.55 $150,858 - $171,896	2,663 Added 14.8%	20,652 $1.2 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $48,562 - $61,058	-782 Reduced 4.17%	17,989 $1.14 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $1 Million - $1.16 Million	13,848 Added 281.29%	18,771 $1.44 Million
Q1 2020 May 26, 2020	BUY	$62.63 - $80.22 $308,327 - $394,923	4,923 New	4,923 $368,000
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $365,446 - $468,083	-5,835 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $3,142 - $3,456	-51 Reduced 0.87%	5,835 $379,000
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $7,063 - $7,797	113 Added 1.96%	5,886 $373,000
Q2 2019 Aug 12, 2019	SELL	$61.87 - $69.38 $3,093 - $3,469	-50 Reduced 0.86%	5,773 $390,000
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $984,159 - $1.1 Million	-15,739 Reduced 72.99%	5,823 $379,000
Q4 2018 Feb 12, 2019	SELL	$60.54 - $79.0 $47,160 - $61,541	-779 Reduced 3.49%	21,562 $1.35 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $95,698 - $111,628	-1,475 Reduced 6.19%	22,341 $1.58 Million
Q1 2018 May 11, 2018	SELL	$72.84 - $88.8 $284,076 - $346,320	-3,900 Reduced 14.07%	23,816 $1.8 Million
Q4 2017 Feb 13, 2018	BUY	$71.15 - $83.52 $213,450 - $250,560	3,000 Added 12.14%	27,716 $1.99 Million
Q3 2017 Nov 13, 2017	SELL	$72.11 - $85.47 $35,333 - $41,880	-490 Reduced 1.94%	24,716 $2 Million
Q2 2017 Aug 11, 2017	BUY	N/A	676 Added 2.76%	25,206 $1.78 Million
Q2 2017 Aug 10, 2017	BUY	N/A	24,530	24,530 $1.76 Million

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.8 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.4 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.88 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.55 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.41 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bahl & Gaynor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bahl & Gaynor Inc with notifications on news.

Account